A systematic review of GWAS identified SNPs associated with outcomes of medications for opioid use disorder

Abstract Background Patients with opioid use disorder (OUD) display an interindividual variability in their response to medications for opioid use disorder (MOUD). A genetic basis may explain the variability in this response. However, no consensus has been reached regarding which genetic variants si...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Caroul Chawar, Alannah Hillmer, Stephanie Sanger, Alessia D’Elia, Balpreet Panesar, Lucy Guan, Dave Xiaofei Xie, Nandini Bansal, Aamna Abdullah, Flavio Kapczinski, Guillaume Pare, Lehana Thabane, Zainab Samaan
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Opioid Pharmacogenetic MOUD Methadone GWAS Systematic review Medicine (General) R5-920 Social pathology. Social and public welfare. Criminology HV1-9960
Acceso en línea:	https://doaj.org/article/5cb8c8e6c2a944c5a05ed746c8958567
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5cb8c8e6c2a944c5a05ed746c8958567
record_format	dspace
spelling	oai:doaj.org-article:5cb8c8e6c2a944c5a05ed746c89585672021-11-28T12:36:08ZA systematic review of GWAS identified SNPs associated with outcomes of medications for opioid use disorder10.1186/s13722-021-00278-y1940-0640https://doaj.org/article/5cb8c8e6c2a944c5a05ed746c89585672021-11-01T00:00:00Zhttps://doi.org/10.1186/s13722-021-00278-yhttps://doaj.org/toc/1940-0640Abstract Background Patients with opioid use disorder (OUD) display an interindividual variability in their response to medications for opioid use disorder (MOUD). A genetic basis may explain the variability in this response. However, no consensus has been reached regarding which genetic variants significantly contribute to MOUD outcomes. Objectives This systematic review aims to summarize genome-wide significant findings on MOUD outcomes and critically appraise the quality of the studies involved. Methods Databases searched from inception until August 21st, 2020 include: MEDLINE, Web of Science, EMBASE, CINAHL and Pre-CINAHL, GWAS Catalog and GWAS Central. The included studies had to be GWASs that assessed MOUD in an OUD population. All studies were screened in duplicate. The quality of the included studies was scored and assessed using the Q-Genie tool. Quantitative analysis, as planned in the protocol, was not feasible, so the studies were analyzed qualitatively. Results Our search identified 7292 studies. Five studies meeting the eligibility criteria were included. However, only three studies reported results that met our significance threshold of p ≤ 1.0 × 10–7. In total, 43 genetic variants were identified. Variants corresponding to CNIH3 were reported to be associated with daily heroin injection in Europeans, OPRM1, TRIB2, and ZNF146 with methadone dose in African Americans, EYS with methadone dose in Europeans, and SPON1 and intergenic regions in chromosomes 9 and 3 with plasma concentrations of S-methadone, R-methadone, and R-EDDP, respectively, in Han Chinese. Limitations The limitations of this study include not being able to synthesize the data in a quantitative way and a conservative eligibility and data collection model. Conclusion The results from this systematic review will aid in highlighting significant genetic variants that can be replicated in future OUD pharmacogenetics research to ascertain their role in patient-specific MOUD outcomes. Systematic review registration number CRD42020169121.Caroul ChawarAlannah HillmerStephanie SangerAlessia D’EliaBalpreet PanesarLucy GuanDave Xiaofei XieNandini BansalAamna AbdullahFlavio KapczinskiGuillaume PareLehana ThabaneZainab SamaanBMCarticleOpioidPharmacogeneticMOUDMethadoneGWASSystematic reviewMedicine (General)R5-920Social pathology. Social and public welfare. CriminologyHV1-9960ENAddiction Science & Clinical Practice, Vol 16, Iss 1, Pp 1-14 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Opioid Pharmacogenetic MOUD Methadone GWAS Systematic review Medicine (General) R5-920 Social pathology. Social and public welfare. Criminology HV1-9960
spellingShingle	Opioid Pharmacogenetic MOUD Methadone GWAS Systematic review Medicine (General) R5-920 Social pathology. Social and public welfare. Criminology HV1-9960 Caroul Chawar Alannah Hillmer Stephanie Sanger Alessia D’Elia Balpreet Panesar Lucy Guan Dave Xiaofei Xie Nandini Bansal Aamna Abdullah Flavio Kapczinski Guillaume Pare Lehana Thabane Zainab Samaan A systematic review of GWAS identified SNPs associated with outcomes of medications for opioid use disorder
description	Abstract Background Patients with opioid use disorder (OUD) display an interindividual variability in their response to medications for opioid use disorder (MOUD). A genetic basis may explain the variability in this response. However, no consensus has been reached regarding which genetic variants significantly contribute to MOUD outcomes. Objectives This systematic review aims to summarize genome-wide significant findings on MOUD outcomes and critically appraise the quality of the studies involved. Methods Databases searched from inception until August 21st, 2020 include: MEDLINE, Web of Science, EMBASE, CINAHL and Pre-CINAHL, GWAS Catalog and GWAS Central. The included studies had to be GWASs that assessed MOUD in an OUD population. All studies were screened in duplicate. The quality of the included studies was scored and assessed using the Q-Genie tool. Quantitative analysis, as planned in the protocol, was not feasible, so the studies were analyzed qualitatively. Results Our search identified 7292 studies. Five studies meeting the eligibility criteria were included. However, only three studies reported results that met our significance threshold of p ≤ 1.0 × 10–7. In total, 43 genetic variants were identified. Variants corresponding to CNIH3 were reported to be associated with daily heroin injection in Europeans, OPRM1, TRIB2, and ZNF146 with methadone dose in African Americans, EYS with methadone dose in Europeans, and SPON1 and intergenic regions in chromosomes 9 and 3 with plasma concentrations of S-methadone, R-methadone, and R-EDDP, respectively, in Han Chinese. Limitations The limitations of this study include not being able to synthesize the data in a quantitative way and a conservative eligibility and data collection model. Conclusion The results from this systematic review will aid in highlighting significant genetic variants that can be replicated in future OUD pharmacogenetics research to ascertain their role in patient-specific MOUD outcomes. Systematic review registration number CRD42020169121.
format	article
author	Caroul Chawar Alannah Hillmer Stephanie Sanger Alessia D’Elia Balpreet Panesar Lucy Guan Dave Xiaofei Xie Nandini Bansal Aamna Abdullah Flavio Kapczinski Guillaume Pare Lehana Thabane Zainab Samaan
author_facet	Caroul Chawar Alannah Hillmer Stephanie Sanger Alessia D’Elia Balpreet Panesar Lucy Guan Dave Xiaofei Xie Nandini Bansal Aamna Abdullah Flavio Kapczinski Guillaume Pare Lehana Thabane Zainab Samaan
author_sort	Caroul Chawar
title	A systematic review of GWAS identified SNPs associated with outcomes of medications for opioid use disorder
title_short	A systematic review of GWAS identified SNPs associated with outcomes of medications for opioid use disorder
title_full	A systematic review of GWAS identified SNPs associated with outcomes of medications for opioid use disorder
title_fullStr	A systematic review of GWAS identified SNPs associated with outcomes of medications for opioid use disorder
title_full_unstemmed	A systematic review of GWAS identified SNPs associated with outcomes of medications for opioid use disorder
title_sort	systematic review of gwas identified snps associated with outcomes of medications for opioid use disorder
publisher	BMC
publishDate	2021
url	https://doaj.org/article/5cb8c8e6c2a944c5a05ed746c8958567
work_keys_str_mv	AT caroulchawar asystematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT alannahhillmer asystematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT stephaniesanger asystematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT alessiadelia asystematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT balpreetpanesar asystematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT lucyguan asystematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT davexiaofeixie asystematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT nandinibansal asystematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT aamnaabdullah asystematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT flaviokapczinski asystematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT guillaumepare asystematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT lehanathabane asystematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT zainabsamaan asystematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT caroulchawar systematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT alannahhillmer systematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT stephaniesanger systematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT alessiadelia systematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT balpreetpanesar systematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT lucyguan systematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT davexiaofeixie systematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT nandinibansal systematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT aamnaabdullah systematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT flaviokapczinski systematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT guillaumepare systematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT lehanathabane systematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder AT zainabsamaan systematicreviewofgwasidentifiedsnpsassociatedwithoutcomesofmedicationsforopioidusedisorder
_version_	1718407892089962496

A systematic review of GWAS identified SNPs associated with outcomes of medications for opioid use disorder

Ejemplares similares